946,083
Inventories 1,017,856 (3,358,488)
Prepaid expenses and other current
assets 2,101,008 986,132
Accounts payable and accrued expenses (22,506) 224,627
Other current payables (169,743) --
Taxes payable (863,589) 1,381,155
Unearned revenue 541,327 39,086
Due to related parties 118,685 --
NET CASH PROVIDED BY OPERATING
ACTIVITIES 16,337,799 4,742,275
CASH FLOWS FROM INVESTING ACTIVITIES:
Deposit on patent right -- (2,827,814)
Payment on intangible assets (8,621,660) (5,862,059)
Purchase of property and equipment (7,166,057) (217,982)
NET CASH (USED IN) INVESTING
ACTIVITIES (15,787,717) (8,907,855)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of convertible debt -- (2,520,000)
Proceeds from sale of convertible
redeemable preferred stocks -- 5,000,000
Payment of debt issuance costs -- (468,568)
Proceeds from related party advances -- 774,571
NET CASH PROVIDED BY FINANCING
ACTIVITIES -- 2,786,003
EFFECT OF EXCHANGE RATE ON CASH 1,476 223,064
NET (DECREASE) INCREASE IN CASH 551,558 (1,156,513)
CASH - beginning of period 1,278,808 4,557,957
CASH - end of period $1,830,366 $3,401,444
SUPPLEMENTAL DISCLOSURE
'/>"/>SOURCE Lotus Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 Related biology technology :1.
Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets2.
Lotus Scarless Hair Transplantation (International) Medical Chain Institute Opens New Center on Beijings Prestigious ChangAn Avenue3.
Lotus Pharmaceuticals Announces Second Quarter 2008 Results4.
NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results5.
Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results6.
Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT7.
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 20098.
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results9.
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT10.
Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States11.
Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement